Source: Wellteq
  • Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX: AHI)
  • Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares
  • AHI has agreed to advance up to A$1,200,000 to Wellteq
  • AHI is a provider of smartphone-based human scanning technology
  • Wellteq is a leading global provider of personalized digital health and wellness solutions
  • Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02

Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX:AHI).

Under the terms of the agreement, AHI will acquire all of the outstanding shares of Wellteq. Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares.

AHI will issue a total of approximately 17,811,508 shares for 100 per cent of Wellteq’s issued shares.

AHI has agreed to advance up to A$1,200,000 to Wellteq. The loan will be advanced in tranches not exceeding A$200,000. Amounts advanced under the loan will be due in six months and will bear interest at a rate of 10 per cent per annum.

AHI is a provider of smartphone-based human scanning technology, with a diverse range of data-driven applications in fitness, mHealth, life & health Insurance, and apparel.

Wellteq is a leading global provider of personalized digital health and wellness solutions. 

Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.